Coherus Biosciences Inc. rose over 30% in US stocks after market hours
六月清晨搅
发表于 2023-12-27 09:40:52
288
0
0
The US stock market of Coherus Biosciences Inc. rose more than 30% after market hours. On December 26th local time, the US Food and Drug Administration (FDA) approved its new cancer drug UDENYCA& Reg; ONBODY. Udenyca is a biologically similar drug to Anjin's cancer drug Neulasta (pegfilgrastim).
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- US chip stocks continue to rise, TSMC gains over 8%
- Bilibili's US stock market rose more than 4% before trading
- Chinese concept stocks and US stocks generally rose before the market opened, with Bilibili rising nearly 4%
- Chinese concept stocks and US stocks generally strengthened before the market opened, and Futu Holdings rose more than 5%
- Bank of America survey: US stock market expected to be the best asset of 2025 after Trump's victory!
- Chinese concept stocks and US stocks mostly rose before the market, with extreme discounts and a nearly 6% increase
- Most US bank stocks rise, with JPMorgan Chase exceeding 1%
- Fuguo Bank's US stock market rose nearly 3% before trading
- RBC Capital raises target prices for multiple US bank stocks
- Micron Technology's US stock fell more than 14% in pre-market trading
